627 The DLL3-targeted half-life extended bispecific T cell engager (HLE BiTE®) immune-oncology therapy AMG 757 has potent antitumor activity in neuroendocrine cancer

by Keegan Cooke, Jinghui Zhan, Juan Estrada, Marie-Anne Damiette Smit, Aditya Shetty, Jonathan Werner, Fei Lee
Published 2020-11-01